絞り込み

16260

広告

「ibritumomab tiuxetan」の検索結果

549件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.

Discriminatory power of the 111-indium scan (111-In) in the prediction of altered biodistribution of radio-immunoconjugate in the 90-yttrium ibritumomab tiuxetan therapeutic regimen: Meta-analysis of five clinical trials and 9 years of post-approval safety data.

Addition of low-dose, involved-field external beam radiotherapy just prior to radioimmunotherapy for CD20+ lymphoma: "Priming" cell death pathways?

Phase II study of short-course CHOP-rituximab followed by (90)y ibritumomab tiuxetan as first-line treatment for follicular lymphoma: Analysis of FcγR variants.

Y(90) ibritumomab tiuxetan with maintenance rituximab as initial therapy for high tumor burden follicular lymphoma: A Wisconsin Oncology Network study.

Use of myeloablative Y90-ibritumomab tiuxetan in patients with high-risk CD20+ NHL not eligible for standard ASCT: Five-year results.

Consolidation therapy with yttrium-90-ibritumomab tiuxetan in follicular lymphoma following induction with modern chemoimmunotherapy regimens: A single-institution experience.

Phase II trial of rituximab and short duration chemotherapy followed by (90)Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial.

High-dose radioimmunotherapy with yttrium 90 ((90)Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL): Update of a phase I/II trial.

Long-term follow-up of a phase I/II trial of radioimmunotherapy (RIT) with yttrium 90 ((90)Y) ibritumomab tiuxetan for CD20+ B-cell non-Hodgkin's lymphoma (NHL).

Analysis of relationship between baseline body weight and efficacy/safety of yttrium 90 ((90)Y) ibritumomab tiuxetan radioimmunotherapy in patients (pts) with non-Hodgkin's lymphoma (NHL).

Low incidence of treatment-related myelodysplastic syndrome (tMDS) and acute myelogenous leukemia (tAML) in patients with non-Hodgkin's lymphoma (NHL) treated with ibritumomab tiuxetan.

Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Yibritumomab tiuxetan: Ten year follow-up of the phase 2 ECOG-ACRIN study E1499.

Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced- Intensity Conditioning (with Melphalan, Fludarabina +/- Thiotepha) for Allogeneic Transplant in Relapsed or Refractory Aggressive B-Cell Lymphoma: a GELTAMO Trial.

Y(90) -Ibritumomab tiuxetan (Y(90) -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05).

Analysis of the influence of (111)In on (90)Y-bremsstrahlung SPECT based on Monte Carlo simulation.

Zevalin(®) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?

A pioneer experience in Malaysia on In-house Radio-labelling of (131)I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose (131)I-rituximab-BEAM conditioning autologous transplant.

Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results.

Long term complication in follicular lymphoma: assessing the risk of second neoplasm in 242 patients treated or not with 90-yttrium-ibritumomab tiuxetan.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
Sort by
※並べ替えは表示に時間がかかります